Prevention of Cognitive Decline in Older Adults With Low Dha/Epa Index in Red Blood Cells

PHASE3CompletedINTERVENTIONAL
Enrollment

774

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Alzheimer Disease
Interventions
DRUG

Omega-3 treatment

"Patient in the treatment comparative arm will consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day)."

DIETARY_SUPPLEMENT

Placebo

"The appearance and taste of the placebo will be similar to those of the active ingredient. Placebo capsules contained a 1:1 ratio of corn oil and soy oil.~36 months consisting of a 18-month placebo-controlled period followed by a 18-month open-label extension period wherein all participants will receive active treatment. Active treatment consists of 1.53 g /day dose of DHA-0 (972 mg /day DHA + 555 mg /day EPA; 3 caps /day).~For the 18 months placebo-controlled period (n=200/arm): 1.53 g /day dose of DHA-0 (972 mg /day DHA + 555 mg /day EPA; 3 caps /day) or placebo (3 similar pills /day)."

Trial Locations (1)

31059

University Hospital Toulouse, Toulouse

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER

NCT03691519 - Prevention of Cognitive Decline in Older Adults With Low Dha/Epa Index in Red Blood Cells | Biotech Hunter | Biotech Hunter